韩国医学与多重用药对老年卒中患者跌倒风险及死亡率的影响
基于韩国国民健康保险服务理赔数据库的回顾性队列研究,纳入2015年首发卒中的65岁以上多重用药(≥5种药物)或超多重用药(≥10种药物)老年患者。经倾向评分匹配后比较韩国医学(以针灸为主)使用者与非使用者的跌倒骨折风险及全因死亡率,随访3年。结果显示韩国医学使用与多重用药者跌倒率较高但全因死亡率较低相关。
要点
- 老年卒中多重用药患者使用韩国医学(针灸为主)与全因死亡率降低相关。
- 多重用药者使用韩国医学跌倒骨折率较高,超多重用药者跌倒风险无显著变化。
- 韩国医学在超多重用药的虚弱人群中降低死亡率而不改变跌倒风险。
核心结论
- 在老年卒中合并多重用药患者中,韩国医学可能改善功能恢复与活动能力,若平衡训练不足可能增加跌倒,但同时带来生存获益。
- 在更虚弱的超多重用药组中,韩国医学降低死亡率而不改变跌倒风险,提示功能获益与竞争风险动态随用药强度而异。
研究设计与样本
- 基于韩国国民健康保险服务理赔数据库的 population-based 回顾性队列研究。
- 纳入2015年首发卒中的65岁以上成人,要求多重用药(≥5种药物)或超多重用药(≥10种药物)持续至少270天。
- 韩国医学使用者定义为卒中发病一年内接受针灸或电针(≥3次门诊或≥1次住院)。
- 共25,034例老年卒中患者,其中10,011例有多重用药,6,809例使用韩国医学;倾向评分匹配后比较3,127例使用者与3,127例非使用者。
主要发现
- 多重用药的韩国医学使用者跌倒率高于非使用者,但全因死亡率低于非使用者。
- 在超多重用药组中,韩国医学使用对跌倒无显著影响,但与较低死亡率相关。
- 未匹配队列的敏感性分析、替代结局定义及交互作用分析呈现一致模式。
关键数值与推荐
- 多重用药定义为≥5种处方药物持续至少270天,超多重用药定义为≥10种。
- 韩国医学暴露定义为卒中发病一年内针灸或电针≥3次门诊或≥1次住院。
- 主要结局为导致骨折的跌倒,次要结局为全因死亡率,均评估3年。
临床怎么用
- 对老年卒中多重用药患者,可考虑将韩国医学(针灸为主)纳入综合卒中照护以可能改善生存。
- 使用韩国医学时需评估并加强平衡训练,因多重用药者跌倒骨折率较高。
- 在超多重用药的虚弱患者中,韩国医学可能降低死亡率而不增加跌倒风险。
局限性
- 需要前瞻性研究采用精细功能测量、药物相互作用数据及正式竞争风险模型,以优化韩国医学安全整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke survivors often take multiple medications (polypharmacy), raising concerns about falls and mortality in older adults. This study investigated whether Korean Medicine (KM)-primarily acupuncture-is associated with fall risk and mortality among older adults with stroke and polypharmacy. METHODS: A population-based retrospective cohort study using South Korea's National Health Insurance Service (NHIS) claims database. Adults aged 65 or older with a first stroke in 2015 were included if they had five or more prescribed medications (polypharmacy) or ten or more (hyper-polypharmacy) for at least 270 days. KM users received acupuncture or electroacupuncture (≥3 outpatient visits or ≥1 inpatient stay) within a year of stroke onset. The primary outcome was falls resulting in fracture; the secondary outcome was all-cause mortality-both assessed over 3 years. Propensity score matching balanced demographics, comorbidities, and medication use. Cox proportional hazards and subgroup analyses were conducted. Subgroup and sensitivity analyses explored effect modification. RESULTS: Among 25,034 older stroke patients, 10,011 had polypharmacy; of those, 6,809 used KM. After matching, 3,127 KM users were compared with 3,127 non-users. KM users with polypharmacy had a higher rate of falls but lower all-cause mortality than non-users. In hyper-polypharmacy, KM use did not significantly affect falls but was associated with lower mortality. Sensitivity analyses of the unmatched cohort, alternative outcome definitions, and interactions yielded consistent patterns. CONCLUSION: In older adults with stroke and polypharmacy, KM may improve functional recovery and mobility, potentially increasing falls if balance training is inadequate, yet simultaneously confer survival advantages-perhaps through neuro-immune or systemic effects-irrespective of medication load. Among the more frail hyper-polypharmacy group, KM reduced mortality without altering falls, suggesting that functional gains and competing-risk dynamics differ by medication intensity. Prospective studies with granular functional measures, drug-drug interaction data, and formal competing-risk models are needed to optimize the safe integration of KM into comprehensive stroke care.
引用
- Lee YS, Jang BH, Jeon JP, et al. Association of Korean Medicine and polypharmacy with fall risk and mortality in older adults with stroke. Front Pharmacol. 2025. PMID: 40612746. doi:10.3389/fphar.2025.1621819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。